Login to Your Account



Roche Gives Up Daclizumab; PDL Seeking Asthma Partner

By Randall Osborne


Monday, November 27, 2006
Hoffmann-La Roche Inc.'s decision to back out entirely of the deal with PDL BioPharma Inc. for Zenapax (daclizumab) leaves intact the biotech firm's main revenue sources - as well as a separate pact with Biogen Idec to develop the same antibody in multiple sclerosis - and Wall Street nipped PDL shares only slightly on the Roche news. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription